Haleon plc

OTCPK:HLNC.F Stock Report

Market Cap: US$43.8b

Haleon Valuation

Is HLNC.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of HLNC.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Fair Value: HLNC.F ($4.93) is trading below our estimate of fair value ($8.69)

Significantly Below Fair Value: HLNC.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HLNC.F?

Key metric: As HLNC.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HLNC.F. This is calculated by dividing HLNC.F's market cap by their current earnings.
What is HLNC.F's PE Ratio?
PE Ratio21.4x
EarningsUK£1.52b
Market CapUK£32.61b

Price to Earnings Ratio vs Peers

How does HLNC.F's PE Ratio compare to its peers?

The above table shows the PE ratio for HLNC.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28.8x
TEVA Teva Pharmaceutical Industries
52.5x11.55%US$37.3b
ZTS Zoetis
20.9x6.22%US$54.9b
RPRX Royalty Pharma
22.5x4.89%US$23.3b
BMY Bristol-Myers Squibb
19.2x0.87%US$113.8b
HLNC.F Haleon
21.4x6.73%US$32.6b

Price-To-Earnings vs Peers: HLNC.F is good value based on its Price-To-Earnings Ratio (21.4x) compared to the peer average (28.8x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does HLNC.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

8 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NDOI Endo
0.3xn/aUS$1.76b
CRMD CorMedix
3.4x4.39%US$556.25m
ORMP Oramed Pharmaceuticals
3.3xn/aUS$134.93m
BTMD biote
2.7x-52.79%US$110.96m
HLNC.F 21.4xIndustry Avg. 20.9xNo. of Companies8PE01632486480+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: HLNC.F is expensive based on its Price-To-Earnings Ratio (21.4x) compared to the US Pharmaceuticals industry average (20.5x).

Price to Earnings Ratio vs Fair Ratio

What is HLNC.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HLNC.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.4x
Fair PE Ratio23.9x

Price-To-Earnings vs Fair Ratio: HLNC.F is good value based on its Price-To-Earnings Ratio (21.4x) compared to the estimated Fair Price-To-Earnings Ratio (23.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HLNC.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$4.93
US$5.59
+13.38%
11.79%US$6.93US$4.49n/a15
Jan ’27US$5.00
US$5.61
+12.13%
11.11%US$6.94US$4.50n/a15
Dec ’26US$4.92
US$5.51
+12.10%
11.20%US$6.84US$4.43n/a15
Nov ’26US$4.64
US$5.45
+17.51%
11.16%US$6.66US$4.14n/a16
Oct ’26US$4.37
US$5.54
+26.73%
10.97%US$6.72US$4.23n/a17
Sep ’26US$4.94
US$5.60
+13.55%
10.76%US$6.77US$4.26n/a17
Aug ’26US$4.69
US$5.52
+17.60%
11.17%US$6.67US$4.18n/a17
Jul ’26US$5.13
US$5.78
+12.76%
12.16%US$6.85US$4.29n/a17
Jun ’26US$5.50
US$5.67
+3.06%
11.64%US$6.73US$4.24n/a17
May ’26US$5.15
US$5.34
+3.83%
9.76%US$6.11US$4.18n/a17
Apr ’26US$5.00
US$5.24
+4.72%
9.24%US$5.94US$4.07n/a17
Mar ’26US$5.00
US$5.08
+1.51%
8.71%US$5.74US$3.96n/a17
Feb ’26US$4.68
US$4.93
+5.39%
9.96%US$5.63US$3.83n/a17
Jan ’26US$4.68
US$5.04
+7.71%
9.97%US$5.80US$3.94US$5.0017
Dec ’25US$4.73
US$5.01
+5.88%
9.86%US$5.78US$3.93US$4.9217
Nov ’25US$4.64
US$5.08
+9.45%
10.08%US$5.87US$3.88US$4.6417
Oct ’25US$5.26
US$5.15
-2.15%
10.79%US$5.98US$3.98US$4.3716
Sep ’25US$5.05
US$4.81
-4.61%
9.30%US$5.67US$3.81US$4.9417
Aug ’25US$4.57
US$4.72
+3.49%
8.16%US$5.22US$3.82US$4.6917
Jul ’25US$4.07
US$4.60
+13.25%
8.48%US$5.18US$3.66US$5.1317
Jun ’25US$4.12
US$4.60
+11.78%
8.27%US$5.21US$3.68US$5.5016
May ’25US$3.90
US$4.51
+15.53%
7.98%US$5.12US$3.62US$5.1516
Apr ’25US$4.17
US$4.54
+8.82%
8.66%US$5.18US$3.66US$5.0015
Mar ’25US$4.17
US$4.59
+9.99%
8.76%US$5.19US$3.67US$5.0015
Feb ’25US$4.16
US$4.60
+10.64%
8.99%US$5.23US$3.70US$4.6815
Jan ’25US$4.10
US$4.52
+10.29%
9.29%US$5.27US$3.70US$4.6816
US$5.61
Fair Value
12.2% undervalued intrinsic discount
15
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/14 14:06
End of Day Share Price 2026/01/14 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Haleon plc is covered by 28 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Iain SimpsonBarclays
Warren AckermanBarclays
Bethan DaviesBerenberg